Spectoceutics ApS: Financial statements 2025
CVR: 44427923
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Spectoceutics ApS (CVR 44427923) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -17,345 and a net result of DKK -13,529. Equity in the 2025 report amounted to DKK 19,423. The solvency ratio was 96.9%.
- Gross Profit
- DKK -17,345
- Profit/Loss
- DKK -13,529
- Equity
- DKK 19,423
- Total Assets
- DKK 20,038
Official annual report
How creditworthy is Spectoceutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Spectoceutics ApS has published its interim report for the period November 9, 2023 to December 31, 2024.
About Spectoceutics ApS
Spectoceutics ApS is a Danish company of the type Anpartsselskab based in Gentofte, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Carsten Højer. The company is owned by Anders Ohlhues Baandrup and Dunnock Holding ApS. In 2025, the company reported a gross profit of DKK -17,345 and a net result of DKK -13,529. Equity in the 2025 report amounted to DKK 19,423.